Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
'We are very pleased with the safety and tolerability profile of Bria-IMT plus immune checkpoint inhibitor (CPI) combination in metastatic breast cancer to date,' stated Dr. William V. Williams, BriaCell's President & CEO. 'The DSMB's second positive data review and recommendation to continue with patient enrollment in BriaCell's pivotal Phase 3 study clinical trial is highly encouraging and further highlights the potential of our groundbreaking novel immunotherapy to treat this urgent medical need.'
'Metastatic breast cancer is a devastating disease for patients and their families, and the DSMB's positive review represents an important step forward towards our goal of transforming cancer care, and improving patients' survival and quality of life outcomes,' noted Giuseppe Del Priore, MD, MPH, BriaCell's Chief Medical Officer. 'We look forward to sharing additional updates from BriaCell's pivotal Phase 3 trial in the coming months.'
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell's clinical advancement of Bria-IMT as a safe and effective treatment option for metastatic cancer patients; the ability of Bria-IMT to transform cancer care in metastatic breast cancer patients; the potential use of the combination regimen for metastatic breast cancer patients; the potential of BriaCell's novel immunotherapy to be a groundbreaking treatment for metastatic breast cancer; and BriaCell sharing additional updates about its pivotal Phase 3 trial in the coming months, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com
Investor Relations Contact:investors@briacell.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
26 minutes ago
- CNBC
CCTV Script 15/08/2025
This week, in addition to the Consumer Price Index (CPI) report, the market has been closely monitoring the latest Producer Price Index (PPI) report released overnight. This latest report has sounded an alarm for the market. Unlike the CPI data earlier this week, which suggested that inflation remains relatively mild, the higher-than-expected PPI data indicates that U.S. tariff policies may be gradually driving up prices at the upstream level of the supply chain. The PPI data reflects price changes at the production level and serves as a leading indicator for consumer prices. When PPI data exceeds expectations, the market perceives greater inflationary pressure at the production level, which could eventually pass through to consumers. This means that the pace of inflation cooling may be slower than expected. Ben Ayers, a senior economist at Nationwide, a U.S. insurance and financial services company, pointed out that so far, most of the increased tariff costs have been absorbed by U.S. businesses. However, rising import prices are increasingly squeezing corporate profit margins. Therefore, it is expected that the pass-through of tariffs to consumer prices will intensify in the coming months, potentially leading to a slight rise in U.S. inflation in the second half of the year. Persistent inflationary pressure means it will be more difficult for the Federal Reserve to initiate rate cuts. Overnight, a former Fed official commented that the market's previous expectations for the Fed to ease monetary policy may have been overly optimistic, and the market is now adjusting its forecasts for the extent of rate cuts. "I think the Fed actually has a little bit higher bar than the markets, I think, in terms of cutting rates. Okay, so, you know, I think that that they could be over, overestimating what will happen in that regard." According to CME FedWatch Tool, just one day earlier, the market had priced in nearly a 6% probability that the Federal Reserve might cut rates by 50 basis points at its September meeting. However, following the release of the PPI data, the market not only slightly reduced the likelihood of a 25-basis-point cut in September but is now assigning about an 8% chance that the Fed will leave rates unchanged. This shift triggered a series of overnight market reactions. U.S. stocks showed mixed performance, with the S&P 500 eking out a marginal 0.03% gain to close at a record high for the third consecutive session, though the upward momentum noticeably weakened. Meanwhile, the Dow Jones Industrial Average and Nasdaq Composite both ended slightly lower. The downward revision of Fed rate-cut expectations also strengthened the U.S. dollar. The Dollar Index rose approximately 0.4% overnight, settling at 98.256. Concurrently, U.S. Treasuries faced selling pressure, pushing yields higher as bond prices fell. The yield on the 10-year Treasury note climbed about 5 basis points to around 4.29%. Market participants are now closely parsing remarks from Fed officials. Overnight, when questioned about whether he would support a 50-basis-point rate cut in September, the President of the Federal Reserve Bank of St. Louis responded: "From my perspective, it's unsupported by the current state of the economy and the outlook for the economy." Next, market focus will shift to the Jackson Hole Economic Symposium scheduled for next week, where Federal Reserve Chair Jerome Powell is set to deliver a speech. Investors are hoping to glean more signals about the future policy direction from his remarks.
Yahoo
34 minutes ago
- Yahoo
JPMorgan Raises PT on Micron (MU), Keeps an Overweight Rating
Micron Technology, Inc. (NASDAQ:MU) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 12, JPMorgan raised the firm's price target on Micron Technology, Inc. (NASDAQ:MU) from $165 to $185, while keeping an Overweight rating on the stock. The improved price target follows the company's updated fiscal fourth quarter 2025 guidance. Micron Technology, Inc. (NASDAQ:MU) had previously projected fourth quarter guidance expecting revenue of $10.7 billion ± $300 million, non-GAAP gross margins between the range of 41% to 43%. However, on August 11, the company updated this guidance and now expects fourth quarter revenue to reach $11.2 billion ± $100 million, with non-GAAP margins in the range of 44% to 44.5%. Management noted that this improved guidance reflects better pricing of DRAM and strong execution. A close-up view of a computer motherboard with integrated semiconductor chips. Micron Technology, Inc. (NASDAQ:MU) designs and manufactures high-performance memory and storage products, including DRAM, NAND, and NOR technologies. While we acknowledge the potential of MU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
37 minutes ago
- Business Insider
Stifel Nicolaus Reaffirms Their Buy Rating on Proficient Auto Logistics, Inc. (PAL)
In a report released on August 15, J. Bruce Chan from Stifel Nicolaus maintained a Buy rating on Proficient Auto Logistics, Inc., with a price target of $13.00. The company's shares closed yesterday at $7.77. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bruce Chan covers the Industrials sector, focusing on stocks such as Forward Air, XPO, and Hub Group. According to TipRanks, Bruce Chan has an average return of 0.7% and a 50.20% success rate on recommended stocks. In addition to Stifel Nicolaus, Proficient Auto Logistics, Inc. also received a Buy from William Blair's Ryan Merkel in a report issued on August 12. However, on August 14, TR | OpenAI – 4o reiterated a Hold rating on Proficient Auto Logistics, Inc. (NASDAQ: PAL). The company has a one-year high of $20.58 and a one-year low of $5.88. Currently, Proficient Auto Logistics, Inc. has an average volume of 179.3K. Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PAL in relation to earlier this year. Earlier this month, Amy F. Rice, the President & COO of PAL sold 6,100.00 shares for a total of $47,702.00.
